NKTR - Nektar Therapeutics

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
45.42
+0.80 (+1.79%)
At close: 4:00PM EST

45.50 +0.08 (0.18%)
After hours: 4:10PM EST

Stock chart is not supported by your current browser
Previous Close44.62
Open44.51
Bid45.15 x 900
Ask46.09 x 1300
Day's Range43.60 - 45.88
52 Week Range29.22 - 111.36
Volume1,943,419
Avg. Volume2,534,817
Market Cap7.862B
Beta (3Y Monthly)3.87
PE Ratio (TTM)10.60
EPS (TTM)4.28
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est78.89
Trade prices are not sourced from all markets
  • Markit12 hours ago

    See what the IHS Markit Score report has to say about Nektar Therapeutics.

    # Nektar Therapeutics ### NASDAQ/NGS:NKTR View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $3.50 billion over the last one-month into ETFs that hold NKTR are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • These beaten-down stocks are expected to roar back in 2019
    MarketWatch3 days ago

    These beaten-down stocks are expected to roar back in 2019

    Dozens of favored S&P 500 stocks have suffered declines of more than 20% since the end of the third quarter.

  • Here's Why Nektar Therapeutics Gave Back 45% in 2018
    Motley Fool3 days ago

    Here's Why Nektar Therapeutics Gave Back 45% in 2018

    Last year started out with a bang, but the excitement didn't last very long.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Nektar Therapeutics.

    # Nektar Therapeutics ### NASDAQ/NGS:NKTR View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Neutral Short interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding NKTR is favorable, with net inflows of $16.47 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here's Why Nektar Therapeutics Surged Today
    Motley Fool9 days ago

    Here's Why Nektar Therapeutics Surged Today

    Investors liked what the company had to say about the year ahead.

  • Investing.com9 days ago

    Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close

    Investing.com - Union Pacific , Motorcar Parts of America and Nektar Therapeutics surged on Tuesday, underpinning a second-straight day of gains in the broader market.

  • A Look at Sarepta Therapeutics’ Recent Developments
    Market Realist10 days ago

    A Look at Sarepta Therapeutics’ Recent Developments

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year. In the third quarter of 2018, the company reported net income and EPS of -$76.4 million and -$1.15, respectively, compared to -$47.7 million and -$0.78 in the third quarter of 2017. Wall Street analysts anticipate that in the fourth quarter of 2018, Sarepta Therapeutics will report net income and EPS of -$63.26 million and -$0.95, respectively. Analysts also estimate that the company will report net income and EPS of -$274.73 million and -$4.16, respectively, in fiscal 2018. Wall Street analysts estimate that BioMarin Pharmaceuticals (BMRN), Nektar Therapeutics (NKTR), and Vertex Pharmaceuticals (VRTX), Sarepta Therapeutics’ peers in the biopharmaceuticals market, will report EPS of around -$0.62, $3.88, and $2.88, respectively, in fiscal 2018. ## Recent developments On January 2, 2019, Sarepta Therapeutics entered a long-term strategic relationship with Aldevron. Aldevron is one of the leading producers of custom proteins, nucleic acids, and antibodies for use in the biotech industry. As per the terms of the agreement, Aldevron will supply plasmid DNA for the fulfillment of Sarepta Therapeutics’ requirements in its gene therapy clinical trials and commercial purposes. Aldevron will specifically supply GMP-grade plasmid for Sarepta Therapeutics’ micro-dystrophin Duchenne muscular dystrophy (or DMD) and Limb-girdle muscular dystrophy (or LGMD) gene therapy programs. As per the terms of the agreement, Aldevron will also supply plasmid for Sarepta Therapeutics’ future gene therapy programs. The agreement is expected to help Sarepta Therapeutics with sufficient plasmid for research and commercial purposes. Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 2 - How Is Sarepta Therapeutics Positioned in January?

  • How Is Sarepta Therapeutics Positioned in January?
    Market Realist10 days ago

    How Is Sarepta Therapeutics Positioned in January?

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million. In the third quarter of 2018, the company’s revenue grew ~71% YoY to $78.5 million from $46.0 million. Wall Street analysts estimate that Sarepta Therapeutics will generate revenues of $85.8 million in the fourth quarter of 2018. Analysts also estimate that the company’s net revenue in fiscal 2018 will be around $301.1 million, which represents ~49.9% YoY growth. In the third quarter of 2018, Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN), Sarepta Therapeutics’ peers in the biopharmaceuticals market, reported revenues of $27.8 million, $783.9 million, and $391.7 million, respectively, which represents a ~81.9% YoY decline, a ~42.04% YoY increase, and a ~17.23% YoY increase. Wall Street analysts estimate that Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN) will generate revenues of $1.2 billion, $3.0 billion, and $1.5 billion, respectively, which represents ~289%, ~37.41%, and ~15% YoY growth. ## Expense trends In the first nine months of 2018, Sarepta Therapeutics’ cost of sales excluding amortization of in-licensed rights amounted to $21.1 million compared to $3.8 million in the same period the prior year. In the first nine months of 2018, Sarepta Therapeutics reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $255.6 million and $143.5 million, respectively, compared to $122.3 million and $90.5 million in the same period the prior year. Wall Street analysts estimate that Sarepta Therapeutics will report cost of sales, SG&A, and R&D expenses of $30.2 million, $190.88 million and $317.02 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • Sarepta Therapeutics Stock Rose 96% in 2018
    Market Realist10 days ago

    Sarepta Therapeutics Stock Rose 96% in 2018

    Who Is Eyeing Sarepta Therapeutics Now? ## Stock performance On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its close of $106.67 on January 3. Sarepta Therapeutics stock grew from $55.64 at the close of market on December 29, 2017, to reach $109.13 at the close of market on December 31, 2018, which represents ~96% growth over 2018. On January 2, 2019, Sarepta Therapeutics stock closed at $107.50, which is ~35% below its 52-week high of $176.50 on June 19, 2018. The company hit its 52-week low of $26.26 on February 13, 2018. ## Recent developments In December 2018, Sarepta Therapeutics (SRPT) completed the submission of its continuing NDA (new drug application) that seeks approval of its golodirsen for the treatment of individuals with Duchenne muscular dystrophy with genetic mutations associated to skipping exon 53 Duchenne gene. Sarepta Therapeutics’ golodirsen is an engineered phosphorodiamidate morpholino oligomer for the treatment of DMD with genetic mutations of skipping exon 53 of the DMD gene. ## Analyst recommendations Of the 24 analysts tracking Sarepta Therapeutics in January 2019, nine of them recommended a “strong buy,” while 14 analysts recommended a “buy” rating. One analyst recommended a “hold” for Sarepta Therapeutics in January. On January 7, Sarepta Therapeutics had a consensus 12-month target price of $194.36, which represents a ~68.38% return on investment over the next 12-months. ## Peers’ ratings In January 2018, of 27 analysts tracking BioMarin Pharmaceuticals (BMRN), ~78% of them recommended “buys.” Of the 11 analysts tracking Exelixis (EXEL), ~73% of them recommended “buys.” Of the 11 analysts tracking Nektar Therapeutics (NKTR), ~82% of them recommended “buys.” On January 7, BioMarin Pharmaceuticals (BMRN), Exelixis (EXEL), and Nektar Therapeutics (NKTR) had a consensus 12-month target price of $120.3, $28.78, and $78.89, respectively, which represents ~38.12%, ~38.83%, and a ~132.30% return on investment over the next 12 months. Continue to Next Part Browse this series on Market Realist: * Part 2 - How Is Sarepta Therapeutics Positioned in January? * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • ACCESSWIRE15 days ago

    Today's Research Reports on Trending Tickers: Celgene and Nektar Therapeutics

    The Dow Jones Industrial Average gained 0.08 percent to close at 23,346.24, while the S&P 500 Index increased 0.13 percent to close at 2,510.03. The Nasdaq Composite Index climbed 0.46 percent to close at 6,665.94. Celgene’s stock jumped 3.98% Wednesday, to close the day at $66.64.

  • ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics
    PR Newswire15 days ago

    ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics

    Nektar will use ImaginAb's CD8 ImmunoPET technology to accelerate the development of its investigational immuno-oncology medicines LOS ANGELES , Jan. 3, 2019 /PRNewswire/ -- ImaginAb Inc., an immuno-oncology ...

  • Business Wire17 days ago

    DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • GlobeNewswire17 days ago

    CLASS ACTION UPDATE for NKTR, FIT, WBT and XRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

  • GlobeNewswire17 days ago

    FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Nektar Therapeutics, Inc. (“Nektar” or the “Company”) (NASDAQ:  NKTR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between November 11, 2017  through October 2, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/nktr. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

  • ACCESSWIRE18 days ago

    FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / December 30, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 11, 2017 and October 2, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before December 31, 2018.

  • GlobeNewswire19 days ago

    NKTR FINAL DEADLINE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important December 31 Deadline in Class Action – NKTR

    NEW YORK, Dec. 29, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from November 11, 2017.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool20 days ago

    3 Top Biotech Stocks to Buy Right Now

    The market's recent panic may be providing opportunities in this notoriously difficult sector.

  • BioXcel Surges on Fast Track Designation to Agitation Drug
    Zacks20 days ago

    BioXcel Surges on Fast Track Designation to Agitation Drug

    BioXcel (BTAI) soars after the FDA granted Fast Track designation to its lead candidate, BXCL501.

  • ACCESSWIRE20 days ago

    Pawar Law Group Reminds of Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

    NEW YORK, NY / ACCESSWIRE / December 28, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) ...

  • ACCESSWIRE20 days ago

    DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018

    NEW YORK, NY / ACCESSWIRE / December 28, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NKTR)and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between November 11, 2017 through October 2, 2018, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

  • GlobeNewswire21 days ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COST, NKTR, FIT and RBBN

    NEW YORK, Dec. 28, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.

  • ACCESSWIRE21 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – NKTR

    NEW YORK, NY / ACCESSWIRE / December 27, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. (''Nektar'' or the ''Company'') (NKTR) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and index under 18-cv-06607, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired shares of Nektar securities between November 11, 2017 through October 2, 2018, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • Spectrum Pharmaceuticals: Financial Overview in December
    Market Realist21 days ago

    Spectrum Pharmaceuticals: Financial Overview in December

    In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY (year-over-year) to $79.9 million from $99.8 million. During this period, the company’s net product sales were $76.4 million, which reflected an ~13% YoY decline. During the same period, the company’s revenues from license fees and services were $3.5 million, which reflected an ~70% YoY decline.

  • Business Wire21 days ago

    MONDAY DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Spectrum Pharmaceuticals: Analysts’ Recommendations in December
    Market Realist21 days ago

    Spectrum Pharmaceuticals: Analysts’ Recommendations in December

    On December 21, Spectrum Pharmaceuticals’ stock price closed at $7.24, which was ~13.30% growth from the close of $6.39 on December 20. On December 20, Spectrum Pharmaceuticals’ stock price declined ~38.79% to $6.39 from the close of $10.44 on December 19. The company hit its 52-week low of $6.22 on December 20.